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Abstract— Elevated cholesterol levels are associated with a
greater risk of developing cardiovascular disease and other
illnesses, making it a prime candidate for detection on a
disposable biosensor for rapid point of care diagnostics. One
of the methods to quantify cholesterol levels in human blood
serum uses an optically mediated enzyme assay and a bench top
spectrophotometer. The bulkiness and power hungry nature of
the equipment limits its usage to laboratories. Here, we present a
new disposable sensing platform that is based on a complemen-
tary metal oxide semiconductor process for total cholesterol quan-
tification in pure blood serum. The platform that we implemented
comprises readily mass-manufacturable components that exploit
the colorimetric changes of cholesterol oxidase and cholesterol
esterase reactions. We have shown that our quantification results
are comparable to that obtained by a bench top spectrophotome-
ter. Using the implemented device, we have measured cholesterol
concentration in human blood serum as low as 29 µM with a
limit of detection at 13 µM, which is approximately 400 times
lower than average physiological range, implying that our device
also has the potential to be used for applications that require
greater sensitivity.
Index Terms— Biosensor, CMOS, colorimetric, diagnostics,
enzyme, photodiode.
I. INTRODUCTION
POINT of care diagnostics are transforming the healthcareindustry, by facilitating the use of home-testing to provide
an early indication of potential illness and disease [1]–[3].
The development of low-cost and effective consumable biosen-
sors [4], [5] is at the forefront of the research for user-
orientated testing, driven in part by the need for rapid diagnosis
and monitoring without overburdening the resources of the
healthcare services. For example, glucose biosensors, have
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become widespread in their use for managing diabetes [6].
Furthermore, metabolite biomarkers of different diseases are
also becoming increasingly well understood [7], [8] which
paves the way for developing new diagnostic system. Here
we report on the development of an electronic device that is
capable of detecting cholesterol whose variable concentrations
are predictive of cardiovascular diseases development [9].
We anticipate that future development will contribute to the
introduction of stratified and precision medicine.
Elevated cholesterol levels are well known for their associ-
ation with an increased risk of coronary heart disease (angina
or heart attack), narrowing of the arteries (atherosclerosis),
stroke, peripheral heart disease, and hypertension [10], [11].
Such conditions often correlated with poor diet, an excessive
fat intake, lack of exercise and other lifestyle choices [12]. This
pose a global threat to public health and consume considerable
healthcare resources [13]. Hence, cholesterol diagnosis has
already entered systematic use in many healthcare systems
with prescription of cholesterol lowering drugs e.g. statins.
It is estimated that approximately 73.5 million adults have
high amounts of LDL∗ cholesterol in the US alone [14] and
approximately 17 million deaths a year, nearly one third of
the total [15], arise through cardiovascular disease.
One of the diagnostic methods for quantifying cholesterol
concentration depends on enzyme-based assays that require
a classical spectrophotometer to measure changes in colour
products from those enzyme reactions [16]. A general purpose
spectrophotometer would incorporate a sophisticated setup of
a white light source, a monochromator containing a diffraction
grating and a light transducer that converts light into electrical
signal such as a charge-coupled device (CCD), a photodiode
or a photomultiplier tube [17]. The wide spectrum range
of the spectrophotometer makes it bulky and power hungry
which consequently confines its usefulness to laboratories and
hospitals.
The working principle of a spectrophotometer to measure
colour changes of enzyme assay depends on setting up the
monochromator’s output light to a specific wavelength that
matches the assay’s absorption peak wavelength. By using
the same principle, in this work we propose a disposable
sensing platform that is designed to operate using a single
wavelength. By careful selection of the right combination
of enzyme absorption wavelength, light source wavelength
and detector spectrum, a simpler-disposable version of the
spectrophotometer can be implemented using components that
can be industrially mass-produced.
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The platform that we have implemented comprises a
complementary metal oxide semiconductor (CMOS)-based
photodiode array and an off-the-shelf light emitting
diode (LED). The photodiode array is fabricated using
commercial standard CMOS process, which is readily
available for low-cost mass-production [18].
Photodiodes made in a CMOS process are generally sen-
sitive to light in the 200 nm to 1100 nm range, owing to
the bandgap of silicon (1.12 eV). This range makes them
suitable for colorimetric enzyme assays that use visible light
or fluorescent mediators, which often use wavelengths in
the range 400 nm to 700 nm. A colour change in this
range of enzyme assays, e.g. cholesterol ester hydrolase [19],
cholesterol dehydrogenase [20], cholesterol esterase [21] and
cholesterol oxidase [22] can be exploited to extract cholesterol
levels. In this work, we have employed cholesterol oxidase and
cholesterol esterase assay to quantify total cholesterol from
human blood serum samples.
II. MATERIALS AND METHODS
A. Assay Materials
Cholesterol oxidase from Streptomyces (C8649,
23 Units/mg solid) was purchased from Sigma-Aldrich, as was
cholesterol (C3045), o-Dianisidine dihydrochloride (F5803),
triethanolamine hydrochloride (T9534), Triton™X-100
(T9284) and horseradish peroxidase (P8250, 163 Units/mg
solid). Cholesterol esterase from Pseudomonas fluorescens
(C9281-5 Units/mg solid) was purchased from Sigma-
Aldrich as was taurocholic acid sodium salt hydrate (T4009)
and sodium cholate hydrate (C1254). Sodium chloride
was purchased from VWR (27810). Human serum from
human male AB plasma, USA origin, sterile-filtered was
sourced from Sigma Aldrich (H4522). The serum cholesterol
concentration was stated as 110 - 210 mg/dl.
B. Enzyme Assay Methods
Approximately 30% of cholesterol in serum is present in
‘free’ form (typically, 40 mg/dl – 85 mg/dl) while the remain-
der is assimilated into cholesteryl esters with long-chain fatty
acids [23]. In order to measure the total cholesterol in serum,
a triple enzyme assay was used comprising two cholesterol
reactions and an optical product step via the activity of
peroxidase. First, the enzyme cholesterol esterase was used
to hydrolyse cholesterol esters to free cholesterol [24]. The
reaction is as below:
Cholesteryl Ester + H2O CholesterolEsterase−−−−−−−−−−−−→ Cholesterol
+ Fatty Acid
(1)
The second reaction involved the addition of cholesterol
oxidase, which is an oxidoreductase that uses molecular oxy-
gen as an electron acceptor to reduce oxygen to hydrogen
peroxide [25]. In this reaction, free cholesterol in serum
with the addition of free cholesterol from cholesterol esterase
reaction is used by the cholesterol oxidase, as a mean of
quantification. The cholesterol oxidase catalysed reaction is
Fig. 1. a) Circuit diagram of a single photodiode pixel. b) Illustrative
waveforms showing how the output voltage responds to three different light
levels. The light intensity is greatest for the curve labeled Vd3. c) Packaging
of the CMOS chip for aqueous measurements. The chip is 3.4 mm × 3.6 mm
with an active area of 1.6 mm × 1.6 mm.
as below:
Cholesterol + O2 CholesterolOxidase−−−−−−−−−−−−→ 4 − Cholesten − 3
− one + H2O2 (2)
The third reaction involved the production of a coloured
product to be measured optically. In the presence of H2O2
produced from cholesterol oxidase, o-Dianisidine is oxidised
to a coloured product with a progressively deep orange colour,
amenable to detection by absorbance of green light. The inten-
sity of the coloured product is dependent on the concentration
of H2O2, which is proportional to cholesterol concentration.
o − Dianisidine(reduced) + H2O2
Peroxidase−−−−−−−→ o − Dianisidine(oxidised)+ H2O (3)
Therefore, these three enzyme reactions allow for a colori-
metric measurement of total cholesterol in serum.
C. CMOS Chip
An integrated circuits chip was designed using Cadence
Design Software version 5.10, and fabricated in the AMS
0.35 µm CMOS process provided by Austriamicrosystems.
The chip incorporates an array of 16 × 16 photodiodes with
integrated addressing and readout circuits. Each chip measured
3.4 mm by 3.6 mm, with an active sensor array area of 1.6 mm
by 1.6 mm. The photodiode pixel used for these experiments
measured 10 µm × 24 µm.
In this chip we used a typical active pixel sensor (APS)
design that incorporates a photodiode and three transistors to
enable the readout of data [26]. The schematic of a single
pixel is shown in Fig. 1a. As can be seen in the timing
diagram of Fig. 1b, each measurement cycle begins at t = t0
when Vrst = Vdd. From t0 to t1 the junction capacitance
of the diode is precharged to be Vdd. At t = t1 the circuit
enters the integration phase. Depending on the integration
time, a different photocurrent Iph corresponds to a change of
the voltage, Vd, across the diode. At t = t2 the diode voltage is
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Fig. 2. a) The implemented diagnostic platform incorporates a CMOS photo-
diode array chip and mbed microcontroller. b) Schematic of the experimental
set up. A green LED provides the excitation light, which is collected by the
photodiodes. As cholesterol oxidase catalyzes the cholesterol reaction, the
oxidation of o-Dianisidine results in fewer photons from the LED reaching
the photodiode and hence a change in voltage from the chip directly infers
the enzyme activity and thus the amount of cholesterol present in solution.
sampled and read-out using the ‘sel’ signal on M3. As can be
seen from Fig. 1b the sampled voltage decreases as the light
intensity is increased (e.g. for traces labelled Vd1 and Vd2).
However, if the detector is saturated, the diode will have
completely discharged before t = t2. This is illustrated by
the trace labelled Vd3.
Fig. 1c shows the CMOS chip after packaging. The chip was
packaged by attaching it to a chip carrier using EPO-TEK H74
epoxy (Epoxy Technology Inc.). The epoxy, heated to 150° C,
formed a strong bond between the chip and the carrier. A wire-
bonding machine was then used to make the connections
between the chip and chip carrier. Next, a 2 mm cube of
polydimethylsiloxane (PDMS) was placed on the sensor active
area as protection before adding EPO-TEK 302-3M (Epoxy
Technology Inc.) to protect the bond-wires. This epoxy was
cured at room temperature for duration of 24 hours. The
PDMS was then removed from the sensor surface before
cleaning the sensor with acetone and isopropanol. Finally,
a section of polypropylene centrifuge tube (Fisherbrand) was
attached with more EPO-TEK 302-3M and cured at 65° C
for 3 hours to allow for aqueous measurements to occur on
the chip surface.
D. Experimental Setup
In order to operate the photodiode array chip, a printed
circuit board (PCB) platform was designed to integrate the
chip with an ARM mbed STM32 Nucleo-F334R8 board
(STMicroelectronics, UK) as shown in Fig. 2a. The mbed
microcontroller was programmed to provide addressing signals
Fig. 3. The spectral response of the photodiode, the enzyme solution after a
reaction has occurred, and the green LED emission characteristics. The peak
in the LED emission intensity occurs very near the optimum in the overlap
in the enzyme absorbance and PD sensitivity spectra.
and to acquire the output readings from the array. These
readings were then transferred by a universal serial bus (USB)
to a computer based LabVIEW program, in which the data was
processed and analysed. Fig. 2b shows the concept of utilising
the experimental setup in conjunction with a LED to quantify
the coloured product from the enzyme assay.
III. EXPERIMENTAL RESULTS AND DISCUSSIONS
A. Optical Evaluation of the System
The optical characteristics of the photodiode and a com-
pleted cholesterol reaction mix, were evaluated to examine
their spectral relationship. First, the spectrum of the photo-
diode was measured using a TMc300 monochromated light
source (Benthem Instruments), swept between 350 nm and
1000 nm. The photodiode responsivity shown in Fig. 3 has a
maximum peak at c. 600 nm. The enzyme spectrum was then
measured using a TFProbe MSP300 spectrometer (Angstrom
Sun Technologies) after all the substrate had been consumed.
The measurement showed that the enzyme spectrum has an
absorption peak at c. 460 nm. From both traces, it can be seen
that there is an overlap between sensitivity of the photodiode
and the absorbance spectrum of the enzyme assay, around
500 nm. Based on this data, a green LED was chosen to have
a peak spectrum close to 500 nm. An off-the-shelf commercial
green LED was measured using the same spectrometer and is
shown to have a peak at 505 nm, which was well positioned
at the overlap of the two traces.
B. Electrical Evaluation of the System
In this section, we present the electrical characteristics of
the photodiode array, in terms of dynamic range and noise
performance. The photodiode array has a minimum light
detection of 280 nW/cm2 and a total dynamic range of 56 dB.
In terms of noise, the chip was designed to have an array
of 256 sensors, which had proven to be able to outperform
a single sensor. In our previous work, we had demonstrated
that an array of ion sensitive field effect transistor (ISFET)
sensors could be used as an average to reduce noise [27].
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Fig. 4. Comparison of the readout signal from a typical pixel and the average
readout of the 16 × 16 array.
In the same way, the photodiode array was used to reduce
the noise of the combined assay signal, since we can obtain
data from a single photodiode, or we can average data from
2 to 28 photodiodes. Following Gaussian statistics, the noise
is reduced as a function of
√
N , where N is the number of
sensors. Fig. 4 illustrates a typical time-course signal obtained
from the chip for a very low concentration of cholesterol. As
can be seen, the signal obtained from a single sensor has a
very large noise, whereas the signal obtained from an average
of all the sensors has a much reduced noise. Therefore, all
the subsequent measurements were done using the average of
all the photodiodes. Furthermore, chip-to-chip variation was
also evaluated using seven different chips and found to have
a standard deviation of 5.8 mV. This slight difference is due
to CMOS process parameter variations, which we minimised
by using control measurement as a reference for each set of
measurements as demonstrated in Section D.
C. Spectrophotometric Measurement to Different Cholesterol
Concentrations
In this section, we have quantified cholesterol in solution
and serum using our proposed enzyme assay, which was mea-
sured with a bench top spectrophotometer. Initially, enzymatic
activity of cholesterol oxidase was evaluated using a coupled
colorimetric assay in which o-Dianisidine, in the presence of
peroxidase and H2O2 (a product of cholesterol oxidase), is
oxidised. The absorbance of the oxidised o-Dianisidine was
monitored at 505 nm (similar to the LED peak) and 25° C
with a UV-2550 Shimadzu Spectrophotometer. 0.5% (w/v)
cholesterol with 10% (w/v) Triton™X-100 was first made
up as stock, which is equivalent to 13 mM. All experiments
were performed using a cuvette with 1 ml of solution and
the enzyme assay mix is shown in Table 1. Absorbance
measurements as a function of time for different cholesterol
concentrations were then obtained using the spectrophotome-
ter. The data in Fig. 5a show clearly that each absorbance
levels have well differentiated magnitudes. As the substrate
concentration is increased so is the final absorbance value.
The velocity of the enzyme reaction was therefore measured
by quantifying the amount of product formed per minute
during the initial stage of the reaction, in order to extract
Michaelis-Menten constant, which was 40 ± 7 µM. Using
Fig. 5. a) Spectrophotometer measurement shows the absorption of oxidised
o-Dianisidine for different cholesterol concentration at wavelength of 505 nm.
b) Velocity measurement of the enzyme reaction and the insert shows
Lineweaver-Burk double reciprocal plot of the enzyme reaction.
TABLE I
ENZYME ASSAY MIX FOR CHOLESTEROL ASSAY
the velocity and cholesterol concentration, the reaction rate
versus concentration plot is presented in Fig. 5b. From the
data, Lineweaver-Burk double reciprocal plot (shown in the
inset of Fig. 5b) is also created using the inverse of the velocity
versus inverse of the cholesterol concentration.
This was then moved on to measure the different dilutions
of serum, which correspond to different cholesterol concen-
trations in solution. The serum was first pre-treated with
cholesterol esterase for 10 minutes at 37°C to release free
cholesterol from the esterified form prior to a reaction taking
place. Serum was added to an assay mix containing 34 mM
triethanolamine pH 7.5, 0.25% (w/v) taurocholic acid sodium
salt hydrate, 0.25% (w/v) sodium cholate hydrate, 0.14% (w/v)
sodium chloride and 0.14 Units cholesterol esterase. Following
preincubation, 0.32 mM o-Dianisidine, 3 Units of peroxidase
244 IEEE SENSORS JOURNAL, VOL. 17, NO. 2, JANUARY 15, 2017
Fig. 6. Activity of cholesterol oxidase with different amounts of enzyme for
a fixed amount of cholesterol. This experiment was used to estimate a good
value of enzyme concentration for the subsequent cholesterol detection trials.
The control measurement (no cholesterol) shows no response as expected. The
initial transients are caused by the mixing of the solution when the cholesterol
oxidase is added.
and 0.3 Units of cholesterol oxidase were added, and the
absorbance of the oxidised o-dianisidine was monitored at
505 nm and 37 ° C with a UV-2550 Shimadzu Spectropho-
tometer. As expected, the results from different serum dilutions
agree well with the results from cholesterol made in solution
(data not shown).
D. Optimizing Enzyme Concentration
We first introduced a control experiment to define a refer-
ence baseline for our measurements. This was then followed
by testing a number of cholesterol oxidase concentrations
to identify which one would give an optimal measurable
response within a short-time period, and which could be
used for subsequent experiments. This was initially tested by
spectrophotometry and later confirmed on the photodiode.
Triethanolamine buffer, o-Dianisidine, cholesterol (prepared
as a solution in Triton™X-100) and peroxidase were added
to the sensor at concentrations described above. The final
cholesterol concentration used in this assay was 0.429 mM
(17.5 mg/dl), as recommended by Sigma. The reaction was
initiated immediately by the addition of cholesterol oxidase
in equivalent reaction volumes. The optical path length from
the sensor surface to the photodiode was therefore the same.
The voltage change observed in Fig. 6 is a direct result
of increasing absorbance over time. The sharp increase in
measured voltage immediately after the peroxidase was a result
of the solution being mixed, a transient effect. The photodiode
chip is very robust and easily withstands repeated cleaning and
reuse by rinsing with acetone, isopropanol and DI water and
blow-drying with nitrogen gas. The data shown in this paper
was taken from one chip for consistency.
As expected, the higher the concentration of cholesterol
oxidase added the more rapid the response, with 0.66 Units of
cholesterol oxidase reaching saturation level of approximately
0.63 V, as shown in Fig. 6. At lower concentrations of
cholesterol oxidase, the voltage increased more slowly, but
did tend towards the same final absorbance (and voltage).
The absence of cholesterol (control experiment) gave no
Fig. 7. a) Photodiode response data as a function of cholesterol concentration
for a fixed enzyme concentration. The sensor displays good separation
between different concentrations of cholesterol. The control, where no choles-
terol is added, shows no response. The initial transients are caused by the
mixing of the solution when the cholesterol oxidase is added. b) The endpoint
voltage level as a function of cholesterol concentration. c) The velocity
measurement of the enzyme reaction in serum. In the insert, we show the
Lineweaver-Burk double reciprocal plot.
response, confirming that the sensor was substrate specific.
This experiment validated the sensor as a means of measuring
cholesterol oxidase enzyme activity and allowed us to select
a concentration of 0.33 Units of cholesterol oxidase for
subsequent experiments, as this concentration gave a quick
temporal response and reliable measurement.
E. Measurement of Photodiode Response to Different
Cholesterol Concentrations in Serum
The photodiode’s response to cholesterol present in serum
was then measured, by first pretreating the serum with choles-
terol esterase followed by the addition of cholesterol oxidase.
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Serum was supplied at a stated cholesterol concentration of
between 2.8 mM – 5.4 mM (110 mg/dl – 210 mg/d). Using
absorption method, the exact value was determined to be
3.5 mM by the National Health Service’s (NHS) laboratories
of The Queen Elizabeth University Hospital, Glasgow. The
stock serum was diluted in triethanolamine buffer to specific
final concentrations so they were within the detectable range
of the photodiode.
Our data shows that the CMOS photodiode/LED sen-
sor system yields variable response to different cholesterol
concentrations, as shown in Fig. 7a. Each of the choles-
terol concentration measurements were repeated three times
for consistency and repeatability using the same chip. The
behaviour we observed was a good match with the spectropho-
tometer data (Fig. 5) indicating that the assay works well on
the CMOS chip and that the miniature optical measurement
system is comparable to conventional lab-based spectropho-
tometry. The voltage readout increased monotonically with
cholesterol concentration. No change in voltage was observed
when cholesterol was omitted. Each reaction reached a differ-
ent final plateau voltage, signifying consumption of substrate
and corresponding to the substrate concentration used.
Endpoint voltages as a function of final cholesterol concen-
tration is plotted in Fig. 7b. As can be noticed, the lowest
cholesterol concentration in pure human blood serum that
we measured is at 29 µM. The limit of detection of the
assay is also determined by taking three times of the standard
deviation from control experiment, which is approximately
13 µM. The total cholesterol in human blood for a healthy
individual should be 5 mM or lower [28], hence our device
has the potential to be also used for more sensitive assays.
Similar to data analysis used for the spectrophotometer, the
initial velocity was plotted against cholesterol concentrations
in serum to calculate the KM value. KM was found to be
80 ± 1 µM using the new method. The data was obtained
using the velocity versus concentration plot and Lineweaver-
Burk double reciprocal plot in Fig. 7c. The result is in good
agreement with the value obtained from the spectrophotometer.
The work has therefore demonstrated that a low-cost and
simple green LED/photodiode system has the capability to
replicate the quantification of cholesterol in serum as a bench
top spectrophotometer.
IV. CONCLUSION
Elevated cholesterol is associated with an increased risk of
developing cardiovascular disease with resultant high levels
of morbidity and mortality. Monitoring the cholesterol levels
of a patient in a point-of-care setting would make significant
progress towards controlling cardiovascular disease, and would
help save the lives of those affected, with a concomitant
reduction in healthcare costs. Currently spectrophotometry is
the gold standard used to determine cholesterol levels. Here,
a method to determine the relative amounts of cholesterol in
serum has been demonstrated using a miniaturised derivation
from the spectrophotometric assay, by using a CMOS system.
The assay method has been shown to be sensitive enough to
detect serum cholesterol levels in a concentration dependent
manner spanning the range of 29 µM to 231 µM, and therefore
has the potential to be further developed as a practical hand-
held sensor device. Future challenges will include creating an
assay sample technology that will allow the fractionation of
blood so that serum can be added onto the sensor.
The use of a CMOS sensor allows the device to be interfaced
to electronic devices and displays, which could lead to more
functional and practical devices using mobile computing. Such
devices could be more easy to use and reliable than test-
strips that often lack a good user interface. The results show
excellent potential for the development of an early-warning
device for the detection of an individual’s elevated cholesterol
– leading to a low-cost and commercial diagnostic tool for
home cholesterol management, which could subsequently spur
the development of similar products for other metabolomic
health indicators using different enzyme assays. In the long
term we anticipate such devices will play a major role in
metabolomic science and precision medicine whereby person-
alized healthcare is made possible through the use of precise
patient data.
NOTES
∗Low density lipoprotein cholesterol, often termed “bad
cholesterol”.
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